United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$304.81 USD
+12.16 (4.16%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $304.88 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
United Therapeutics Corporation's dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
UTHR 304.81 +12.16(4.16%)
Will UTHR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
Other News for UTHR
United Therapeutics (UTHR) Launches $1 Billion Share Buyback
United Therapeutics (UTHR) Launches $1B Stock Buyback Program
United Therapeutics enters $1B accelerated share repurchase program
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program | ...
United Therapeutics announces $1B accelerated share repurchase program